Cayuga Biotech
Cayuga Biotech is dedicated to harnessing the body's innate ability to halt bleeding and heal, addressing significant unmet needs in hemorrhage control and bleeding disorders through proprietary science and innovative solutions.
Industries
Nr. of Employees
small (1-50)
Awards
CAY001 - Intravenous Agent for Hemorrhage Control
Funding (ceiling)
$3,092,802.7
Award Year
2023
Products
Optimized polyphosphate-derived systemic injectable hemostatic therapy (lead program, late preclinical)
An optimized formulation of short-chain polyphosphate complexed with nanoparticles developed for systemic administration to accelerate hemostatic control in acute major hemorrhage (intended for non-compressible bleeding sites).
Discovery-stage polyphosphate-derived composition for inherited bleeding disorders
A discovery-stage composition based on polyphosphate chemistry being explored as a potential treatment approach for inherited bleeding disorders.
Optimized polyphosphate-derived systemic injectable hemostatic therapy (lead program, late preclinical)
An optimized formulation of short-chain polyphosphate complexed with nanoparticles developed for systemic administration to accelerate hemostatic control in acute major hemorrhage (intended for non-compressible bleeding sites).
Discovery-stage polyphosphate-derived composition for inherited bleeding disorders
A discovery-stage composition based on polyphosphate chemistry being explored as a potential treatment approach for inherited bleeding disorders.
Expertise Areas
- Hemostasis and hemorrhage therapeutics
- Preclinical hemorrhage model testing
- Nanoparticle–polymer formulation for systemic delivery
- Translational medicine and drug discovery
Key Technologies
- Polyphosphate-based therapeutics
- Silica nanoparticle–polymer complexation
- Systemic injectable drug delivery
- In vitro coagulation assays (clotting kinetics)
Key People
Chief Executive Officer
Founder, Chief Science Officer
Corporate and Business Affairs
Clinical Operations
Translational Medicine
Chief Executive Officer
Founder, Chief Science Officer
Corporate and Business Affairs
Clinical Operations
Translational Medicine
Featured In Technology Showcase
Cayuga Biotech Presents Preclinical Data on Lead Product PolyP-SNP for Hemorrhage Contol
Cayuga Biotech has advanced a novel injectable clotting agent—polyP-SNP—that rapidly generates thrombin and promotes safe, targeted clotting. Promising results were presented at ISTH 2024, and a Phase 1 clinical trial is expected to begin by the end of the year.
Rapid Injectable Hemorrhage Control for Noncompressible Bleeding
Supported by the MTEC Military Prototype Advancement Initiative (MPAI) award MTEC-21-06-MPAI-078, Cayuga Biotech is developing CAY001, an injectable drug designed to rapidly control noncompressible internal bleeding. Now in a Phase 1 clinical trial, CAY001 has the potential to improve warfighter survivability by enabling fast, field-deployable treatment of life-threatening hemorrhage.
News & Updates
Cayuga Biotech received recognition for its outstanding oral presentation at a prestigious symposium.
Cayuga Biotech is set to present its latest research findings at the upcoming ISBS meeting.
Cayuga Biotech will showcase its research at the ASH Annual Meeting.
Cayuga Biotech announced promising data regarding its PolyP-SNP complex in addressing battlefield hemorrhage.
Cayuga Biotech revealed data showing significant improvements in coagulation speed in life-threatening situations.
Cayuga Biotech took part in a panel discussion focused on women in biotech.
Cayuga Biotech received recognition for its outstanding oral presentation at a prestigious symposium.
Cayuga Biotech is set to present its latest research findings at the upcoming ISBS meeting.
Cayuga Biotech will showcase its research at the ASH Annual Meeting.
Cayuga Biotech announced promising data regarding its PolyP-SNP complex in addressing battlefield hemorrhage.
Cayuga Biotech revealed data showing significant improvements in coagulation speed in life-threatening situations.
Cayuga Biotech took part in a panel discussion focused on women in biotech.